Veterinary Culture and Susceptibility Sampling: Antimicrobial Selection and Treatment Review

Veterinary clinicians making antimicrobial decisions based on culture results require a cross-species framework that guides sample collection, susceptibility interpretation, antimicrobial selection, and treatment outcome review. This article provides that framework for use in dogs, cats, horses, cattle, sheep, and other species encountered in clinical practice. The approach integrates published evidence from veterinary medicine, including local antibiogram data, ex vivo models of antimicrobial activity, and emerging resistance mechanisms, to support clinical decision-making. The content is organized into practical sections covering sample collection technique, laboratory interpretation, antimicrobial selection logic, treatment review protocols, and common failure patterns. Every section includes concrete management decisions, observations, records, limitations, and professional escalation criteria.

At a Glance: Culture and Susceptibility Decision Framework

Core Principles of Culture and Susceptibility Testing

Culture and susceptibility testing provides laboratory evidence to guide antimicrobial selection. The goal is to match the antimicrobial agent to the bacterial pathogen based on in vitro susceptibility while accounting for host factors, infection site, and regulatory requirements. The Merck Veterinary Manual describes culture and susceptibility testing as a cornerstone of rational antimicrobial therapy. The World Organisation for Animal Health emphasizes that antimicrobial use should be based on laboratory diagnosis whenever possible to preserve antimicrobial effectiveness.

The decision to collect a culture sample should be made before administering any antimicrobial. A single dose of an antimicrobial can suppress bacterial growth enough to produce a false-negative culture result. If the animal has already received antimicrobials, document the drug, dose, route, and timing on the laboratory submission form. The laboratory may still be able to isolate organisms if the antimicrobial has been discontinued for 48 to 72 hours, depending on the drug half-life and infection site.

Culture results must be interpreted in the context of the clinical presentation. A positive culture from a normally sterile site such as joint fluid, cerebrospinal fluid, or blood is clinically significant. A positive culture from a site with normal bacterial flora such as the skin, respiratory tract, or gastrointestinal tract requires correlation with clinical signs, cytology, and quantitative growth assessment. The AAHA resources on antimicrobial stewardship recommend that clinicians interpret culture results alongside Gram stain and cytology findings.

Sample Collection Techniques by Species and Site

Urine Collection

Urine culture is indicated for animals with clinical signs of urinary tract infection, recurrent urinary tract infections, or when empirical therapy has failed. The preferred collection method is cystocentesis, which avoids contamination from the distal urethra and genital tract. For dogs and cats, cystocentesis is performed with the animal in lateral recumbency using a 22-gauge needle attached to a 6 to 12 mL syringe. The bladder is palpated and stabilized, and the needle is inserted through the ventral abdominal wall. A study published in Acta Veterinaria Scandinavica evaluated the Flexicult Vet system for detection, identification, and antimicrobial susceptibility testing of bacterial uropathogens in small animal practice, demonstrating that rapid diagnostic methods can support timely treatment decisions.

For horses, urine can be collected by free catch during urination or by catheterization. Free catch samples are acceptable for culture if the perineal area is cleaned and the sample is collected midstream. Catheterization carries a risk of introducing bacteria into the bladder and should be performed aseptically. For cattle and sheep, urine can be collected by manual stimulation of the vulva or by catheterization in restrained animals.

Record the collection method, time, and any visible abnormalities on the submission form. Urine samples should be refrigerated if processing is delayed beyond 30 minutes. Refrigeration preserves bacterial viability for up to 24 hours for most uropathogens.

Respiratory Sample Collection

Respiratory infections in cattle, horses, and small animals require careful sample collection to avoid contamination with upper respiratory flora. For bovine respiratory disease, deep nasopharyngeal swabs or transtracheal washes provide samples from the lower respiratory tract. A study published in Veterinary Research Communications evaluated rapid detection of causative bacteria including multiple infections of bovine respiratory disease using 16S rRNA amplicon-based nanopore sequencing, highlighting the potential for molecular methods to supplement traditional culture.

For horses with pneumonia, transtracheal aspiration or bronchoalveolar lavage is preferred. The sample should be placed in a sterile container and transported to the laboratory within two hours. For small animals, endotracheal wash or bronchoalveolar lavage is performed under sedation or anesthesia. The sample should be evaluated for cytology and submitted for aerobic culture and susceptibility testing.

For sheep and goats with respiratory signs, deep nasal swabs or lung lavage samples can be collected. The sample should be placed in transport medium if processing is delayed. Record the sample type, collection method, and any antimicrobial pretreatment on the submission form.

Wound and Abscess Sampling

Wound cultures should be collected from deep tissue or the leading edge of the wound after debridement. Surface swabs of chronic wounds often grow contaminants or colonizing organisms instead of the true pathogen. For abscesses, aspirate pus using a sterile needle and syringe after disinfecting the overlying skin. Submit the aspirate in a sterile container or in an anaerobic transport vial if anaerobic infection is suspected.

For surgical site infections, collect samples before starting antimicrobial therapy. A study published in the Journal of Equine Veterinary Science evaluated antimicrobial activity of ceftiofur and penicillin with gentamicin against Escherichia coli and Streptococcus equi subspecies zooepidemicus in an ex vivo model of equine postpartum uterine disease. The study found that treatment with procaine penicillin G with gentamicin achieved at least bacteriostatic activity against E. coli in both fluid types and bactericidal activity against S. zooepidemicus in both fluid types. This work demonstrates the importance of testing antimicrobial activity in infection-site-specific conditions.

For footrot in sheep, collect samples from the interdigital space after cleaning the foot. A study published in PLOS One examined how reviewing the evidence changes veterinary surgeons beliefs regarding the treatment of ovine footrot. The study found that evidence review can shift treatment preferences, underscoring the value of culture-guided therapy.

Milk Sample Collection

Milk culture is indicated for clinical mastitis cases and for monitoring subclinical infections in dairy herds. Collect the sample aseptically after cleaning the teat end with alcohol. Discard the first three streams of milk, then collect the sample into a sterile tube. Label the tube with the cow identification, quarter, and collection date. Refrigerate the sample and submit to the laboratory within 24 hours.

For goats and sheep with mastitis, follow the same aseptic technique. Record the stage of lactation and any previous treatments on the submission form. The laboratory should perform aerobic culture and susceptibility testing on all clinical mastitis samples.

Joint Fluid and Cerebrospinal Fluid Collection

Joint fluid and cerebrospinal fluid are normally sterile sites. Any bacterial growth from these samples is clinically significant. Collect joint fluid by arthrocentesis using aseptic technique. Place the fluid in a sterile tube and submit for aerobic and anaerobic culture. For cerebrospinal fluid, collect by cisternal or lumbar puncture under general anesthesia or heavy sedation. Submit the fluid in a sterile tube and request aerobic culture and susceptibility testing.

Record the volume collected, appearance, and cell count on the submission form. If the sample volume is small, prioritize culture over cytology. The laboratory should be notified that the sample is from a normally sterile site so that they use appropriate culture methods.

Laboratory Interpretation of Susceptibility Results

Minimum Inhibitory Concentration and Disk Diffusion

Susceptibility testing is performed using either minimum inhibitory concentration (MIC) determination or disk diffusion. MIC testing provides a quantitative measure of the lowest concentration of an antimicrobial that inhibits visible bacterial growth. Disk diffusion provides a qualitative result based on the zone of inhibition around an antimicrobial disk. Both methods classify bacteria as susceptible, intermediate, or resistant based on clinical breakpoints established for the specific animal species.

The Merck Veterinary Manual states that MIC values are preferred for guiding therapy in serious infections because they allow comparison with achievable tissue concentrations. Disk diffusion is acceptable for routine infections and is less expensive. The laboratory report should include the MIC value or zone diameter, the interpretation, and the breakpoints used.

Clinical Breakpoints and Species-Specific Interpretation

Clinical breakpoints are established by organizations such as the Clinical and Laboratory Standards Institute (CLSI) for specific animal species. Breakpoints differ between species because of differences in drug pharmacokinetics, protein binding, and tissue distribution. Using human breakpoints for veterinary isolates can lead to inappropriate antimicrobial selection.

A study published in the Journal of the American Veterinary Medical Association demonstrated the importance of local culture and susceptibility data by evaluating antibiograms from dogs at a veterinary tertiary care center. The study found that local susceptibility patterns can differ from national or regional data, supporting the need for practice-specific antibiograms. Clinicians should request that their laboratory provide species-specific breakpoints and should maintain a local antibiogram for common pathogens.

Interpreting Intermediate Results

An intermediate result indicates that the antimicrobial may be effective if used at a higher dose or at a site where the drug concentrates. For example, an intermediate result for a beta-lactam antimicrobial in a urinary tract infection may be clinically effective because the drug concentrates in urine. For tissue infections, an intermediate result should prompt selection of an alternative antimicrobial with a susceptible result.

Document the interpretation and the rationale for antimicrobial selection in the medical record. If an intermediate result is used to guide therapy, note the infection site and the expected drug concentration at that site.

Recognizing Resistance Patterns

Resistance patterns provide information about the mechanism of resistance and the likelihood of cross-resistance to other antimicrobials. For example, methicillin-resistant Staphylococcus pseudintermedius is resistant to all beta-lactam antimicrobials, including cephalosporins. Extended-spectrum beta-lactamase producing Enterobacteriaceae are resistant to most penicillins and cephalosporins.

A study published in Scientific Reports documented the emergence of transferable tigecycline and eravacycline resistance gene tet(X4) in Escherichia coli isolates from Iran. This finding highlights the global spread of resistance genes and the importance of susceptibility testing for all antimicrobial classes, including newer agents.

Record the resistance pattern in the medical record and flag the case for infection control measures if the organism is multidrug-resistant. Multidrug-resistant organisms require contact precautions and environmental disinfection to prevent spread to other animals.

Antimicrobial Selection Based on Culture Results

Matching Susceptibility to Infection Site

Antimicrobial selection should be based on the susceptibility result, the infection site, and the drug pharmacokinetics. An antimicrobial with a susceptible result may not be effective if it does not reach therapeutic concentrations at the infection site. For example, aminoglycosides are poorly distributed into the central nervous system and are not effective for meningitis even if the organism is susceptible in vitro.

For urinary tract infections, select an antimicrobial that concentrates in urine. Beta-lactams, fluoroquinolones, and trimethoprim-sulfonamides achieve high urinary concentrations. For respiratory infections, select an antimicrobial with good lung tissue penetration. Macrolides, tetracyclines, and fluoroquinolones achieve therapeutic concentrations in respiratory tissues.

For skin and soft tissue infections, select an antimicrobial with good tissue distribution. Beta-lactams, clindamycin, and fluoroquinolones are commonly used. For bone and joint infections, select an antimicrobial with good bone penetration. Fluoroquinolones and clindamycin achieve therapeutic bone concentrations.

Considering Withdrawal Periods and Regulatory Requirements

For food-producing animals, antimicrobial selection must account for withdrawal periods for meat and milk. The World Organisation for Animal Health provides international standards for antimicrobial use in food animals. Clinicians must ensure that the selected antimicrobial has an approved withdrawal period for the species and that the client is informed of the withdrawal period.

For horses, antimicrobial selection must account for the horse's status as a food animal in some jurisdictions. The AVMA resources on antimicrobial stewardship recommend that clinicians verify the regulatory status of each antimicrobial before prescribing.

For dogs and cats, withdrawal periods are not typically required, but clinicians should consider the potential for adverse effects and drug interactions. Record the antimicrobial, dose, route, frequency, and duration in the medical record.

Empirical Therapy While Awaiting Culture Results

Empirical antimicrobial therapy may be necessary while awaiting culture results. The choice of empirical therapy should be based on the most likely pathogen, local susceptibility patterns, and the severity of the infection. For mild infections, a narrow-spectrum antimicrobial is appropriate. For severe infections, a broad-spectrum antimicrobial or combination therapy may be necessary.

The AAHA resources on antimicrobial stewardship recommend that empirical therapy be reviewed when culture results become available. If the empirical therapy is not supported by the susceptibility results, the antimicrobial should be changed to a more appropriate agent.

Document the rationale for empirical therapy in the medical record. Include the suspected pathogen, the expected susceptibility pattern, and the plan for reviewing culture results.

Combination Therapy Considerations

Combination therapy is indicated for certain infections, including mixed infections, severe infections, and infections caused by organisms with inducible resistance. The ACVAA resources on perioperative antimicrobial use provide guidance on combination therapy for surgical patients.

Combination therapy should be based on synergy testing or on known synergistic combinations. For example, a beta-lactam combined with an aminoglycoside provides synergy against Enterobacteriaceae and Pseudomonas aeruginosa. Combination therapy should not be used routinely because it increases the risk of adverse effects and promotes resistance.

Record the rationale for combination therapy in the medical record. Include the expected synergy and the plan for monitoring for adverse effects.

Treatment Review Protocols

Timing of Treatment Review

Treatment review should occur at 48 to 72 hours after starting antimicrobial therapy. The review should assess clinical response, including resolution of fever, improvement in appetite, reduction in pain, and normalization of laboratory parameters. If the animal has not improved, the clinician should consider repeating culture and susceptibility testing, changing the antimicrobial, or investigating for complications such as abscess formation or foreign body.

A study published in Preventive Veterinary Medicine evaluated the prevalence of antimicrobial resistance from bacterial culture and susceptibility records from horse samples in South Africa. The study found high levels of resistance to commonly used antimicrobials, supporting the need for treatment review and repeat culture in cases of treatment failure.

Document the treatment review in the medical record. Include the clinical parameters assessed, the response to therapy, and any changes made to the treatment plan.

Repeat Culture Indications

Repeat culture is indicated when the animal does not respond to therapy, when the infection recurs after treatment, or when the initial culture was collected after antimicrobial administration. Repeat culture should be collected from the same site using the same aseptic technique. The laboratory should be informed that this is a repeat culture so that they can compare results.

For urinary tract infections, repeat culture is indicated 7 to 14 days after completing therapy to confirm eradication. For respiratory infections, repeat culture is indicated if clinical signs persist or recur. For wound infections, repeat culture is indicated if the wound is not healing or if there is purulent discharge.

Record the indication for repeat culture in the medical record. Include the initial culture results, the treatment administered, and the clinical response.

De-escalation and Streamlining

De-escalation refers to changing from a broad-spectrum antimicrobial to a narrow-spectrum antimicrobial based on culture results. Streamlining refers to changing from combination therapy to monotherapy when the susceptibility results support a single agent. Both practices reduce antimicrobial pressure and decrease the risk of resistance.

The World Organisation for Animal Health recommends that antimicrobial use be reviewed and de-escalated whenever possible. Clinicians should have a plan for de-escalation at the time of initial antimicrobial selection.

Document the de-escalation or streamlining decision in the medical record. Include the rationale and the expected benefit.

Duration of Therapy

The duration of antimicrobial therapy should be based on the infection site, the severity of the infection, and the clinical response. For uncomplicated urinary tract infections, 7 to 14 days of therapy is typically sufficient. For pyelonephritis, 14 to 21 days may be necessary. For respiratory infections, 7 to 14 days is typical. For bone and joint infections, 4 to 8 weeks may be necessary.

A study published in Infectious Diseases in Clinical Practice evaluated predictive factors in asymptomatic bacteriuria treatment. The study found that treatment of asymptomatic bacteriuria did not improve outcomes and may contribute to resistance. This finding supports the recommendation to treat only symptomatic infections.

Record the planned duration of therapy in the medical record. Include the criteria for stopping therapy and the plan for follow-up.

Records and Measurements

Culture and Susceptibility Record Keeping

Maintain a record of all culture and susceptibility results in the medical record. The record should include the animal identification, sample type, collection date, laboratory name, bacterial identification, MIC values or zone diameters, interpretation, and the antimicrobial selected. The record should also include the dose, route, frequency, and duration of therapy.

For food-producing animals, maintain records of antimicrobial use as required by regulatory authorities. The World Organisation for Animal Health provides guidelines for record keeping in food animal practice.

Antibiogram Development

An antibiogram is a summary of susceptibility patterns for a specific population of animals over a defined time period. Antibiograms should be developed annually for common pathogens. The antibiogram should include the number of isolates tested, the percentage susceptible for each antimicrobial, and the species and sample type.

A study published in the Journal of the American Veterinary Medical Association demonstrated the importance of local culture and susceptibility data by evaluating antibiograms from dogs at a veterinary tertiary care center. The study found that local antibiograms provide more relevant information than national or regional data.

To develop an antibiogram, collect all culture and susceptibility results from the past year. Include only the first isolate per animal per infection episode. Calculate the percentage susceptible for each antimicrobial. Present the data in a table format for easy reference.

Treatment Outcome Tracking

Track treatment outcomes for all animals that receive antimicrobial therapy. The outcome should be classified as resolved, improved, no change, or worsened. For animals that do not resolve, document the reason for treatment failure and any changes made to the treatment plan.

For food-producing animals, track treatment outcomes at the herd level. Monitor for changes in treatment success rates over time. A decrease in treatment success may indicate emerging resistance or a change in pathogen prevalence.

Record treatment outcomes in the medical record and in the practice management software. Use the data to inform future antimicrobial selection and to identify areas for improvement.

Common Failure Patterns

Sample Collection Errors

Sample collection errors are a common cause of culture failure. Errors include collecting the sample after antimicrobial administration, using contaminated equipment, collecting from a site with normal flora, and submitting an inadequate volume. To avoid these errors, collect the sample before antimicrobial administration, use sterile equipment, collect from the active infection site, and submit an adequate volume.

If the culture result does not match the clinical presentation, consider the possibility of a sample collection error. Repeat the culture using proper technique.

Laboratory Errors

Laboratory errors include misidentification of bacteria, incorrect susceptibility testing, and reporting errors. To minimize laboratory errors, use a laboratory that participates in proficiency testing and that follows CLSI guidelines. If a culture result is unexpected, contact the laboratory to discuss the result and request repeat testing if indicated.

Interpretation Errors

Interpretation errors occur when clinicians use human breakpoints for veterinary isolates, when they ignore intermediate results, or when they select an antimicrobial that does not reach therapeutic concentrations at the infection site. To avoid interpretation errors, use species-specific breakpoints, consider intermediate results in the context of the infection site, and select antimicrobials based on pharmacokinetics.

Treatment Adherence Failures

Treatment adherence failures occur when clients do not administer the antimicrobial as prescribed. To improve adherence, provide clear instructions, use the simplest dosing regimen possible, and schedule follow-up appointments. For food-producing animals, ensure that the person administering the antimicrobial is trained in proper technique.

Limitations of Culture and Susceptibility Testing

In Vitro to In Vivo Disconnect

In vitro susceptibility does not always predict in vivo efficacy. Factors that affect in vivo efficacy include drug pharmacokinetics, protein binding, tissue penetration, biofilm formation, and the host immune response. A study published in the Journal of Equine Veterinary Science evaluated the antimicrobial activity of ceftiofur and penicillin with gentamicin against E. coli and S. zooepidemicus in an ex vivo model of equine postpartum uterine disease. The study found that antimicrobial activity differed between standard culture broth and equine postpartum uterine fluid, demonstrating the importance of testing in infection-site-specific conditions.

Clinicians should consider the possibility of an in vitro to in vivo disconnect when an animal does not respond to therapy despite a susceptible result. In such cases, consider repeating culture, changing the antimicrobial, or investigating for complications.

Fastidious and Anaerobic Organisms

Some bacteria are fastidious and do not grow on standard culture media. Anaerobic bacteria require special transport and culture conditions. If an anaerobic infection is suspected, collect the sample in an anaerobic transport vial and notify the laboratory.

Molecular methods such as 16S rRNA sequencing can detect fastidious and anaerobic organisms that do not grow in culture. A study published in Veterinary Research Communications evaluated rapid detection of causative bacteria including multiple infections of bovine respiratory disease using 16S rRNA amplicon-based nanopore sequencing. This technology may become more widely available in the future.

Polymicrobial Infections

Polymicrobial infections involve multiple bacterial species. Culture results may identify only the predominant organism or the organism that grows best on the culture media. Clinicians should consider the possibility of polymicrobial infections when the culture result does not explain the clinical presentation.

For polymicrobial infections, select an antimicrobial that covers all identified pathogens or use combination therapy. Consider the possibility of synergistic or antagonistic interactions between antimicrobials.

Biofilm-Associated Infections

Biofilm-associated infections are difficult to treat because bacteria in biofilms are less susceptible to antimicrobials. Biofilm formation is common in implant-associated infections, chronic wounds, and respiratory infections in animals with underlying lung disease.

A study published in Frontiers in Veterinary Science screened essential oils for antimicrobial, antiviral, immunomodulatory, and antibiofilm activities against bovine respiratory pathogens. The study found that certain essential oils had antibiofilm activity, suggesting potential alternative strategies for biofilm-associated infections.

For biofilm-associated infections, consider using antimicrobials that penetrate biofilms, such as fluoroquinolones and rifampin. Surgical removal of the biofilm may be necessary.

Welfare and Safety Context

Animal Welfare Considerations

Antimicrobial therapy should be administered in a way that minimizes pain and distress. For painful injections, use the smallest needle size possible and inject into a site with adequate muscle mass. For oral medications, use palatable formulations when available.

The AVMA resources on animal health and welfare provide guidance on pain management and humane handling during veterinary procedures. Clinicians should ensure that animals are properly restrained during sample collection and antimicrobial administration.

Human Safety Considerations

Antimicrobials can cause adverse effects in humans who handle them. Beta-lactams can cause allergic reactions in sensitized individuals. Aminoglycosides can cause ototoxicity and nephrotoxicity. Fluoroquinolones can cause tendonitis and tendon rupture.

The World Organisation for Animal Health provides guidelines for safe handling of antimicrobials in veterinary practice. Clinicians should wear gloves when handling antimicrobials and should wash hands after administration.

Environmental Considerations

Antimicrobials can enter the environment through animal waste and can contribute to the development of antimicrobial resistance in environmental bacteria. The World Organisation for Animal Health recommends that antimicrobial use be minimized and that waste be managed properly.

Clinicians should educate clients about proper disposal of unused antimicrobials. Unused antimicrobials should not be flushed down the toilet or disposed of in household trash.

Professional Escalation Criteria

When to Refer to a Specialist

Referral to a specialist is indicated when the infection does not respond to therapy, when the organism is multidrug-resistant, when the infection involves a site that requires specialized surgical management, or when the animal has an underlying condition that complicates therapy.

The ACVAA resources on perioperative antimicrobial use provide guidance on when to involve a veterinary anesthesiologist for animals with critical illness. The AVMA resources on antimicrobial stewardship provide guidance on when to consult a veterinary microbiologist or infectious disease specialist.

When to Report to Regulatory Authorities

Reporting to regulatory authorities is required for certain infections and for certain antimicrobial-resistant organisms. The World Organisation for Animal Health provides guidelines for reporting antimicrobial resistance in food animals.

Clinicians should be familiar with the reporting requirements in their jurisdiction. Reportable infections include anthrax, brucellosis, and tuberculosis. Reportable antimicrobial-resistant organisms include methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

When to Implement Infection Control Measures

Infection control measures should be implemented when a multidrug-resistant organism is identified. Measures include isolating the animal, using contact precautions, and disinfecting the environment.

The AAHA resources on infection control provide guidance on implementing infection control measures in veterinary practice. Clinicians should have a written infection control plan that includes protocols for managing animals with multidrug-resistant infections.

Practical Decision Framework: Integrating Culture Results with Clinical Pharmacokinetics and Host Factors

Selecting an antimicrobial based solely on a susceptible laboratory result does not guarantee clinical success. The disconnect between in vitro susceptibility and in vivo efficacy is a documented limitation of culture-guided therapy. A study published in the Journal of Equine Veterinary Science evaluating antimicrobial activity against Escherichia coli and Streptococcus equi subspecies zooepidemicus found that treatment outcomes differed between standard bacterial culture broth and equine postpartum uterine fluid, demonstrating that infection-site conditions alter antimicrobial performance. Clinicians need a practical decision framework that integrates culture results with drug pharmacokinetics, infection site physiology, and host immune status to improve treatment outcomes.

Step 1: Classify the Infection Site Compartment

The first decision point after receiving a culture result is to classify the infection site into one of three pharmacokinetic compartments. Compartment 1 includes sites where antimicrobials concentrate through active secretion or filtration, such as the urinary tract, biliary system, and gastrointestinal lumen. For these sites, an intermediate susceptibility result may be clinically effective because drug concentrations exceed serum levels by 10 to 100 times. Compartment 2 includes sites with moderate drug penetration, such as skin, soft tissue, respiratory tract, and bone. For these sites, only susceptible results should guide therapy, and the drug must achieve therapeutic concentrations at the tissue level. Compartment 3 includes sites with limited drug penetration due to physiologic barriers, such as the central nervous system, eyes, prostate, and synovial joints. For these sites, only antimicrobials with documented penetration should be selected, and higher doses or extended duration may be necessary.

Record the infection site compartment classification in the medical record. For example, a urinary tract infection with an intermediate result for amoxicillin may be treated successfully because amoxicillin concentrates in urine. The same intermediate result for a skin infection would require selection of an alternative antimicrobial.

Step 2: Evaluate Host Immune Status and Infection Chronicity

Host immune status directly affects the likelihood of treatment success. Immunocompromised animals, including those with endocrinopathies, neoplasia, chronic viral infections, or those receiving immunosuppressive medications, require more aggressive antimicrobial selection and longer treatment durations. For these animals, select antimicrobials with bactericidal activity instead of bacteriostatic activity whenever possible. Bactericidal antimicrobials include beta-lactams, fluoroquinolones, aminoglycosides, and metronidazole. Bacteriostatic antimicrobials include tetracyclines, macrolides, and sulfonamides.

Infection chronicity also influences treatment approach. Acute infections, defined as less than 7 days duration, are more likely to respond to antimicrobial therapy alone. Chronic infections, defined as more than 14 days duration, are more likely to involve biofilm formation, tissue necrosis, or foreign body contamination. For chronic infections, consider surgical debridement, implant removal, or biofilm-penetrating antimicrobials such as fluoroquinolones or rifampin. A study published in Frontiers in Veterinary Science screened essential oils for antibiofilm activity against bovine respiratory pathogens, finding that certain essential oils demonstrated antibiofilm effects. While essential oils are not standard therapy, this research highlights the importance of considering biofilm in chronic infections.

Record the host immune status and infection chronicity in the medical record. Note any immunosuppressive conditions or medications. Document the estimated duration of infection based on history and clinical findings.

Step 3: Match Antimicrobial Pharmacokinetics to Infection Site

After classifying the infection site and evaluating host factors, select an antimicrobial with pharmacokinetics that match the site. For urinary tract infections, beta-lactams, fluoroquinolones, and trimethoprim-sulfonamides achieve high urinary concentrations. For respiratory infections, macrolides, tetracyclines, and fluoroquinolones achieve therapeutic lung tissue levels. For central nervous system infections, only antimicrobials that cross the blood-brain barrier should be used, including third-generation cephalosporins, fluoroquinolones, metronidazole, and trimethoprim-sulfonamides. For bone and joint infections, fluoroquinolones and clindamycin achieve therapeutic bone concentrations.

For food-producing animals, verify that the selected antimicrobial has an approved withdrawal period for the species and intended use. The World Organisation for Animal Health provides international standards for antimicrobial use in food animals. Record the withdrawal period on the treatment record and communicate it to the client.

Step 4: Apply the 48-Hour Decision Rule

The 48-hour decision rule provides a structured approach to treatment review. At 48 hours after starting antimicrobial therapy, assess the animal using objective criteria. For febrile animals, document the temperature trend. For animals with localized infections, document changes in swelling, discharge, or pain. For animals with systemic signs, document appetite, attitude, and hydration status.

If the animal shows clear improvement, continue the current antimicrobial for the planned duration. If the animal shows partial improvement, continue therapy but schedule re-evaluation at 72 hours. If the animal shows no improvement or deterioration, repeat culture and susceptibility testing, change the antimicrobial based on the original culture results, or investigate for complications such as abscess formation, foreign body, or biofilm.

A study published in Preventive Veterinary Medicine evaluating antimicrobial resistance from horse samples in South Africa found high levels of resistance to commonly used antimicrobials, supporting the need for treatment review and repeat culture in cases of treatment failure. Document the 48-hour assessment in the medical record, including the criteria used and the decision made.

Step 5: Document the Decision Pathway

Documenting the decision pathway ensures accountability and provides data for future treatment decisions. For each antimicrobial selection, record the infection site compartment, host immune status, infection chronicity, antimicrobial pharmacokinetics, and the 48-hour assessment. This documentation supports de-escalation, streamlining, and antibiogram development.

The AAHA resources on antimicrobial stewardship recommend that clinicians maintain detailed records of antimicrobial use. For food-producing animals, regulatory authorities may require documentation of antimicrobial selection rationale. The World Organisation for Animal Health provides guidelines for record keeping in food animal practice.

Common Failure Patterns in the Decision Framework

Failure to classify the infection site compartment correctly is a common error. For example, treating a prostate infection with an antimicrobial that does not penetrate prostatic tissue, such as most beta-lactams, will likely fail even if the organism is susceptible in vitro. Prostatic infections require antimicrobials with basic properties that trap in acidic prostatic fluid, such as fluoroquinolones or trimethoprim-sulfonamides.

Failure to account for host immune status is another common error. Immunocompromised animals may require bactericidal antimicrobials, higher doses, or longer durations. A study published in the Journal of the American Veterinary Medical Association evaluating antibiograms from dogs at a veterinary tertiary care center found that local susceptibility patterns can differ from national data, supporting the need for practice-specific antibiograms. However, even with appropriate antimicrobial selection, immunocompromised animals may fail therapy due to inadequate host response.

Failure to apply the 48-hour decision rule leads to prolonged ineffective therapy. Continuing an antimicrobial for 7 to 14 days without reassessment increases the risk of adverse effects and promotes resistance. The 48-hour rule provides a structured trigger for re-evaluation.

Records and Measurements for the Decision Framework

Maintain a log of all antimicrobial selections that includes the infection site compartment, host immune status, infection chronicity, antimicrobial selected, and 48-hour outcome. Review this log quarterly to identify patterns of treatment failure. If treatment failure rates exceed 20 percent for a specific infection type, investigate for emerging resistance, changes in pathogen prevalence, or errors in the decision framework.

For food-producing animals, track treatment outcomes at the herd level. Monitor for changes in treatment success rates over time. A decrease in treatment success may indicate emerging resistance or a change in pathogen prevalence. The World Organisation for Animal Health recommends that antimicrobial use be reviewed and de-escalated whenever possible.

Professional Escalation Criteria for the Decision Framework

Referral to a specialist is indicated when the decision framework fails to produce clinical improvement after two antimicrobial courses. Referral is also indicated when the infection involves a site that requires specialized surgical management, such as septic joints, deep abscesses, or implant-associated infections. The ACVAA resources on perioperative antimicrobial use provide guidance on when to involve a veterinary anesthesiologist for animals with critical illness.

Consultation with a veterinary microbiologist is indicated when the organism is multidrug-resistant or when the susceptibility pattern is unusual. The AVMA resources on antimicrobial stewardship provide guidance on when to consult a specialist. Record the consultation and the recommendations in the medical record.

Frequently Asked Questions

How should I collect a urine sample for culture from a cat that is difficult to restrain?

For cats that are difficult to restrain, consider sedation with an appropriate protocol before cystocentesis. The cat should be placed in lateral recumbency, and the bladder should be palpated and stabilized. A 22-gauge needle attached to a 6 mL syringe is inserted through the ventral abdominal wall. If cystocentesis is not possible, a free catch sample can be collected using nonabsorbable litter in a clean litter box. The sample should be refrigerated and submitted within 24 hours.

What does an intermediate susceptibility result mean for clinical decision-making?

An intermediate result indicates that the antimicrobial may be effective if used at a higher dose or at a site where the drug concentrates. For urinary tract infections, an intermediate result for a beta-lactam antimicrobial may be clinically effective because the drug concentrates in urine. For tissue infections, an intermediate result should prompt selection of an alternative antimicrobial with a susceptible result. Document the rationale for using an intermediate result in the medical record.

How long should I wait before repeating culture after starting antimicrobial therapy?

Repeat culture should be performed 48 to 72 hours after starting antimicrobial therapy if the animal has not improved. For urinary tract infections, repeat culture is indicated 7 to 14 days after completing therapy to confirm eradication. For respiratory infections, repeat culture is indicated if clinical signs persist or recur. Collect the sample using the same aseptic technique as the initial culture.

Can I use human breakpoints for veterinary isolates if veterinary breakpoints are not available?

Human breakpoints should be used only when veterinary breakpoints are not available and when the drug pharmacokinetics are similar between the species. Differences in drug metabolism, protein binding, and tissue distribution can make human breakpoints inappropriate for veterinary isolates. Contact the laboratory to request species-specific breakpoints or consult published veterinary breakpoints from CLSI.

What should I do if the culture result shows a different organism than expected?

If the culture result shows a different organism than expected, consider the possibility of sample contamination. Review the sample collection technique and the clinical presentation. If the organism is a known pathogen for the infection site, treat based on the susceptibility result. If the organism is likely a contaminant, repeat the culture using proper aseptic technique.

How do I develop a practice-specific antibiogram?

To develop a practice-specific antibiogram, collect all culture and susceptibility results from the past year. Include only the first isolate per animal per infection episode. Calculate the percentage susceptible for each antimicrobial. Present the data in a table format for easy reference. Update the antibiogram annually. A study published in the Journal of the American Veterinary Medical Association demonstrated the importance of local culture and susceptibility data by evaluating antibiograms from dogs at a veterinary tertiary care center.

When is combination antimicrobial therapy indicated?

Combination therapy is indicated for mixed infections, severe infections, and infections caused by organisms with inducible resistance. Combination therapy should be based on synergy testing or on known synergistic combinations. For example, a beta-lactam combined with an aminoglycoside provides synergy against Enterobacteriaceae and Pseudomonas aeruginosa. Combination therapy should not be used routinely because it increases the risk of adverse effects and promotes resistance.

What are the most common causes of treatment failure despite a susceptible culture result?

Common causes of treatment failure include poor drug penetration at the infection site, biofilm formation, presence of a foreign body or abscess, polymicrobial infection, and host immunosuppression. A study published in the Journal of Equine Veterinary Science found that antimicrobial activity differed between standard culture broth and equine postpartum uterine fluid, demonstrating the importance of infection-site-specific factors. If treatment failure occurs, repeat culture and consider investigating for complications.

Related Veterinary Guides

• Livestock Nutrition And Feed Management A Cross Species Decision Framework
• Veterinary Science
• Blood Gas Analysis And Acid Base Interpretation In Veterinary Patients
• Veterinary Clinical Methods Procedures Surgical Interventions
• Hematology Cbc Blood Smear

References and Further Reading

• www.avma.org
• www.aaha.org
• www.acvaa.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Demonstrating the importance of local culture and susceptibility data: antibiograms from dogs at a veterinary tertiary care center.. Journal of the American Veterinary Medical Association, 2023.
• Emergence of transferable tigecycline and eravacycline resistance gene tet(X4) in Escherichia coli isolates from Iran.. Scientific reports, 2025.
• Optimization and evaluation of Flexicult® Vet for detection, identification and antimicrobial susceptibility testing of bacterial uropathogens in small animal veterinary practice.. Acta veterinaria Scandinavica, 2015.
• Prevalence of antimicrobial resistance from bacterial culture and susceptibility records from horse samples in South Africa.. Preventive veterinary medicine, 2017.
• Investigation of Antibiotic Susceptibility Patterns in Bacteria Isolated During a Male Sheep Castration Surgery.. Archives of Razi Institute, 2025.
• Feline gastrointestinal eosinophilic sclerosing fibroplasia in a young ragdoll cat: with surgical management.. Veterinary research communications, 2025.
• Screening and selection of essential oils for an intranasal spray against bovine respiratory pathogens based on antimicrobial, antiviral, immunomodulatory, and antibiofilm activities. Frontiers in Veterinary Science, 2024.
• Rapid detection of causative bacteria including multiple infections of bovine respiratory disease using 16S rRNA amplicon-based nanopore sequencing. Veterinary research communications, 2024.
• Antimicrobial Activity of Ceftiofur and Penicillin With Gentamicin Against Escherichia coli and Streptococcus equi Subspecies zooepidemicus in an Ex Vivo Model of Equine Postpartum Uterine Disease.. Journal of Equine Veterinary Science, 2019.
• Antimicrobial use in the surgical patient.. The Veterinary clinics of North America. Small animal practice, 2006.
• How Does Reviewing the Evidence Change Veterinary Surgeons' Beliefs Regarding the Treatment of Ovine Footrot? A Quantitative and Qualitative Study. Plos One, 2013.
• Predictive Factors in Asymptomatic Bacteriuria Treatment: Results From a Single-Center Rural Veterans Hospital. Infectious Diseases in Clinical Practice, 2025.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.